Dare Bioscience, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Dare Bioscience, Inc. (DARE) on December 5, 2022, reporting an event that occurred on December 1, 2022. The company is a biotechnology firm focused on developing long-acting reversible contraceptives (LARC), specifically the DARE-LARC1 program.
Key Financial Metrics
The filing reports a specific non-dilutive funding event rather than comprehensive financial statements.
- Grant Payment Received: Approximately $4.4 million from the Bill & Melinda Gates Foundation.
- Cumulative Grant Funding: Approximately $23.8 million received to date under the Grant Agreement.
- Total Potential Grant Value: Up to $48.95 million available over the grant period.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change is the receipt of the $4.4 million grant payment, increasing the total non-dilutive funding received under the existing agreement with the Bill & Melinda Gates Foundation. This funding supports technology development and preclinical activities for the DARE-LARC1 program.
Outlook, Risks, and Contingencies
Future payments under the Grant Agreement are contingent upon the achievement of specified development and reporting milestones for the DARE-LARC1 program during the Grant Period (June 30, 2021, to November 1, 2026). The funding is designated for nonclinical proof of principle studies.
Investor Verification Checklist
- Verify the specific development milestones required to unlock the remaining potential funding of approximately $25.15 million.
- Confirm the current cash runway and burn rate in the company's most recent 10-Q or 10-K to assess the impact of this $4.4 million injection.
- Review the status of the DARE-LARC1 nonclinical proof of principle studies to gauge the likelihood of meeting future grant contingencies.